NASDAQ$SRDX
Surmodics Inc · Q3 2020 earnings
Q3 2020 earnings · · Investor relations
Briefing
Reported revenue increase of 10% year-over-year and GAAP EPS of $0.18.
Surmodics reported a revenue increase of 10% year-over-year, with GAAP EPS at $0.18 and non-GAAP EPS at $0.21. The company achieved critical milestones with CE Mark for SurVeil DCB and FDA clearance for Sublime PTA balloon catheter.
- Revenue increased by 10% year-over-year.
- GAAP EPS was $0.18, and non-GAAP EPS was $0.21.
- CE Mark was received for SurVeil drug coated balloon (DCB).
- FDA clearance was received for Sublime radial-access 0.014” PTA balloon catheter.
Headline financials
Revenue & EPS history
Surmodics · Revenue · Quarterly
$26.9M
Revenue by segment
Surmodics · $26.9M total across 2 segments · Q3 2020
- Medical Device$20.5M+8.3%76.3%
- In Vitro Diagnostics$6.37M+18.0%23.7%
Forward guidance
Due to the continued uncertainty surrounding the duration and magnitude of the COVID-19 pandemic, the Company will not provide financial guidance at this time.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 6 quarterly earnings reports
+1.4%
Avg return
Earnings day
+3.0%
Avg return
5 days after
+6.9%
Avg return
30 days after
59%
37 / 63 earnings
Positive
+34.5%
Q2 2024
Best reaction
-13.1%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | +0.6% | +8.5% | -8.0% | |
| Q2 2025 | -1.5% | +2.5% | +7.6% | |
| Q1 2025 | -4.1% | -4.5% | -7.3% | |
| Q4 2024 | +2.0% | +2.3% | +6.2% | |
| Q3 2024 | -0.5% | -1.2% | -4.5% | |
| Q2 2024 | +34.5% | +26.5% | +64.1% | |
| Q1 2024 | -9.8% | -13.0% | -9.6% | |
| Q4 2023 | +1.0% | — | — | |
| Q3 2023 | +4.7% | — | — | |
| Q2 2023 | -2.4% | — | — | |
| Q1 2023 | +4.1% | — | — | |
| Q4 2022 | -3.0% | — | — | |
| Q3 2022 | -7.8% | — | — | |
| Q2 2022 | -1.2% | — | — | |
| Q1 2022 | -11.0% | — | — | |
| Q4 2021 | -11.4% | — | — | |
| Q3 2021 | +3.7% | — | — | |
| Q2 2021 | -5.4% | — | — | |
| Q1 2021 | +15.1% | — | — | |
| Q4 2020 | -2.1% | — | — | |
| Q3 2020 | +0.5% | — | — | |
| Q2 2020 | +3.4% | — | — | |
| Q1 2020 | +6.6% | — | — | |
| Q4 2019 | -13.1% | — | — | |
| Q3 2019 | +13.7% | — | — | |
| Q2 2019 | +0.6% | — | — | |
| Q1 2019 | +17.0% | — | — | |
| Q4 2018 | -11.5% | — | — | |
| Q3 2018 | +11.2% | — | — | |
| Q2 2018 | +7.2% | — | — | |
| Q1 2018 | -0.4% | — | — | |
| Q4 2017 | +0.2% | — | — | |
| Q3 2017 | +1.8% | — | — | |
| Q2 2017 | -7.9% | — | — | |
| Q1 2017 | +1.4% | — | — | |
| Q4 2016 | -6.2% | — | — | |
| Q3 2016 | +8.9% | — | — | |
| Q2 2016 | +14.8% | — | — | |
| Q1 2016 | +8.3% | — | — | |
| Q4 2015 | -2.4% | — | — | |
| Q3 2015 | +9.8% | — | — | |
| Q2 2015 | -2.6% | — | — | |
| Q1 2015 | +3.6% | — | — | |
| Q4 2014 | -3.6% | — | — | |
| Q3 2014 | +2.1% | — | — | |
| Q2 2014 | -4.6% | — | — | |
| Q1 2014 | +7.8% | — | — | |
| Q4 2013 | -3.6% | — | — | |
| Q3 2013 | +10.6% | — | — | |
| Q2 2013 | -6.9% | — | — | |
| Q1 2013 | +1.6% | — | — | |
| Q4 2012 | +0.9% | — | — | |
| Q3 2012 | +10.0% | — | — | |
| Q2 2012 | -1.8% | — | — | |
| Q1 2011 | -1.4% | — | — | |
| Q1 2012 | -1.0% | — | — | |
| Q4 2011 | +1.6% | — | — | |
| Q4 2009 | +1.6% | — | — | |
| Q2 2011 | +1.6% | — | — | |
| Q3 2010 | +1.3% | — | — | |
| Q4 2010 | +1.3% | — | — | |
| Q3 2011 | +1.3% | — | — | |
| Q2 2010 | +1.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro